These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23208928)

  • 1. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
    Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM
    J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Succony L; Gómez-López S; Pennycuick A; Alhendi ASN; Davies D; Clarke SE; Gowers KHC; Wright NA; Jensen KB; Janes SM
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34385275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
    Zhang X; Song Q; Wei C; Qu J
    Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
    Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
    Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia.
    Nagata M; Nakamura T; Sotozono C; Inatomi T; Yokoi N; Kinoshita S
    PLoS One; 2014; 9(4):e93164. PubMed ID: 24709893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
    Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
    Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
    Li W; Zhou Y
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30487162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
    Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aryl Hydrocarbon Receptor Defect Attenuates Mitogen-Activated Signaling through Leucine-Rich Repeats and Immunoglobulin-like Domains 1 (LRIG1)-Dependent EGFR Degradation.
    Hsu HL; Chen HK; Tsai CH; Liao PL; Chan YJ; Lee YC; Lee CC; Li CH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
    Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
    J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRIG and cancer prognosis.
    Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
    Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
    Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
    Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
    Wang Y; Poulin EJ; Coffey RJ
    Br J Cancer; 2013 May; 108(9):1765-70. PubMed ID: 23558895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
    Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
    J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1
    Chen X; Cai G; Liu C; Zhao J; Gu C; Wu L; Hamilton TA; Zhang CJ; Ko J; Zhu L; Qin J; Vidimos A; Koyfman S; Gastman BR; Jensen KB; Li X
    J Exp Med; 2019 Jan; 216(1):195-214. PubMed ID: 30578323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
    Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
    Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TTF-1/Nkx2.1 functional connection with mutated EGFR relies on LRIG1 and β-catenin pathways in lung cancer cells.
    Zamboni M; Civitareale D
    Biochem Biophys Res Commun; 2018 Nov; 505(4):1027-1031. PubMed ID: 30314701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. [Altered Treg and IL-1A Expression in the Immune Microenvironment 
of Lung Squamous-cell Cancer after EGFR Blockade].
    He H; Qi L; Hou Y
    Zhongguo Fei Ai Za Zhi; 2017 Mar; 20(3):143-148. PubMed ID: 28302215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Autonomous Role of EGFR in Spontaneous Duodenal Tumors in LRIG1 Null Mice.
    Niitsu H; Lu Y; Huh WJ; Love AM; Franklin JL; Coffey RJ
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1159-1162.e4. PubMed ID: 33989815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.